Vincent Isore | IP3 | Getty Images
View of the company's logo at Sanofi's general shareholders' meeting on May 4, 2016.
The French pharmaceutical company Sanofi is close to acquiring the biotech company Bioverativ for $ 105 per share, valuing the Hemophilia manufacturer at about $ 11.4 billion, according to a person familiar with the matter.
The offer represents a premium of 63 percent of Friday's closing price of Bioverativ and would be all in cash.
Bioverativ is a spin-out of biotech giant Biogen and earned $ 274.8 million in third-quarter revenue from its two hemophilia products – that was 27 percent more than the previous quarter, although the franchise faces growing competition from Roche and, later on the line, from gene therapy performed by BioMarin, Spark Therapeutics and others.
Sanofi, based in Paris, had been at the table of two of the largest biotechnology deals in recent years, but had appeared empty-handed: Johnson & Johnson purchased Actelion for $ 30 billion in January 2017 and Pfizer acquired Medivation for $ 14 billion in August 2016.
Representatives from Sanofi and BioVerativ did not respond immediately to requests for comments on Sunday night.